All In Biotech

Drug Trial Radar · NCT05337592

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 1815368 Administered as Oral Solution to Healthy Male Subjects (SRD Part), and a Randomised, Open-label, Single-dose, Three-way Cross-over Part Investigating Relative Bioavailability of BI 1815368 as Tablet Versus Oral Solution and Tablet With and Without Food in Healthy Male Subjects (BA Part)

Last checked: Nov 20, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jun 14, 2022

Primary completion

Oct 18, 2022

Study completion Oct 18, 2022

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Single-rising dose (SRD) part The main objectives of the SRD part of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1815368 in healthy male subjects following oral administration of single rising doses. Bioavailability (BA) part The main objective of the BA part is to investigate the relative bioavailability of a tablet formulation versus oral solution and to assess the influence of food on the relative bioavailability of the tablet formulation.

Conditions

  • Healthy

Interventions

  • BI 1815368 formulation 1Drug

    BI 1815368 formulation 1

  • PlaceboDrug

    Placebo

  • BI 1815368 formulation 2Drug

    BI 1815368 formulation 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SRD part: Occurrence of any treatment-emergent adverse eventTime frame: Up to Day 14
  2. BA part: Area under the concentration-time curve of BI 1815368 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to Day 5
  3. BA part: Maximum measured concentration of BI 1815368 in plasma (Cmax)Time frame: Up to Day 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Humanpharmakologisches Zentrum Biberach

    Biberach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.